BioAtla Corp (BCAB): Price-to-Revenue Ratio

Brandmark of bioatla.com (BCAB)

The price/sales multiple of BioAtla, Inc. (BCAB) exhibits volatility linked to the US development of antibodies that minimize toxicity through tumor-specific activation. The 0.30 metric reflects current valuation dynamics, while the business relies on non-cyclical demand and an absence of seasonality. Stability is ensured by science-driven management successfully advancing innovative protocols through clinical trial stages.

BCAB BioAtla P/S Multiple (07/04/2022 - 09/06/2026)

BioAtla, Inc. (BCAB) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price bioatla.com|BCAB - Price Target Chart
- stock exchange capitalization data:
Market Value BioAtla Corp|BCAB - Total Company Value
- issuer book value statistics:
Net Asset Value per Share BioAtla|BCAB - Book Capitalization|Market Value to Equity Ratio bioatla.com|BCAB - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital BioAtla, Inc.|BCAB - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital bioatla.com|BCAB - Company Total Debt|Debt to Book Capital BioAtla Corp|BCAB - Company Long-Term Debts|Company Short-Term Loans and Borrowings BioAtla|Immediate Liquidity bioatla.com
- earnings and multiples data:
BCAB - Company Net Income|Expected Net Income BioAtla, Inc.|BCAB - P/E Multiple|Forward P/E Multiple bioatla.com|BCAB - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio BioAtla Corp|BCAB - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months BioAtla|BCAB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months bioatla.com|BCAB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year BioAtla, Inc.
- issuer revenue and sales details:
BCAB - Company Revenue|Company Expected Sales Volume bioatla.com|BCAB - P/S Multiple|Forward P/S Multiple BioAtla Corp
Summary company analytics:BioAtla Inc
Mass-produced product of BioAtla

The ratio is calculated by dividing the market capitalization of BioAtla, Inc. (BCAB) by its total annual sales. This metric determines the extent to which investors are overpaying per unit of revenue, reflecting market expectations for future earnings. For a developer of selective cancer antibodies, such an analysis is critical, as the business value is based on the commercialization potential of unique technologies. The price-to-sales ratio dynamics allow for the rapid identification of speculative price deviations from fundamental basics.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab Biopharma IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics Inc HRTX|Market Cap to Revenue NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Market Capitalization-to-Revenue Ratio|Corbus Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume CRDF (Cardiff Oncology Inc.)|BeyondSpring - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: P/S Multiple|Price to Sales Cellectar Corp (CLRB)|Price-to-Revenue Ratio BioLineRx Ltd.|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|GTHX: P/S Multiple|KRON (Kronos Bio Inc) - Price-to-Revenue Ratio|KTRA (Kintara) - P/S Multiple|Oncternal Corp (ONCT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Portage Biotech Inc. (PRTG)